Tagged with UK

Otsuka (Philippines) Pharmaceutical You were appointed President and General Manager of Otsuka Philippines in 2008. Can you please start by giving to our readers an overview of Otsuka activities in the country as well as the company’s biggest achievements since you have been heading the company? Otsuka Philippines was incorporated in December 1997…

State Institute for Drug Control (SUKL) Mr. Březovký, can you begin with an introduction to SUKL and its role within the Czech Republic’s complex regulatory environment? I would like to begin by noting that I have been at my position as director of SUKL from the 1st of May of this year—today, I have been six…

UCB Ukraine It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you took this position and was has been accomplished so far? Within many years and before 2008 our company had been represented in Ukraine by…

Sanofi Ukraine What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies have an LLC now, for two key reasons. Firstly, it is risky to become too big and visible while continuing…

Ipsen Ukraine Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian operations of Ipsen been faring in comparison to the global performance of the company? Let me first provide you a…

Astellas Ukraine Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi and then later as Astellas once the merger was complete. Since then, the company has been quite active with a…

Chiltern UK Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as the UK? I am confident that the UK will remain a key region for research and innovation for the global…

Bayer UK/Ireland Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave mature markets, such as the UK and how do you aim to position the company locally? The UK is perceived…

Actelion UK and Ireland Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational groups to a company like Actelion that specializes in rare diseases? I spent the first major part of my career…

Ferring Pharmaceuticals UK Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing on board that is unique from your past experiences? As you mentioned, I have quite an extensive career and would…

Nycomed UK Ltd. Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why Servier has invested more in Australia of late. What drives Servier’s headquarters to conduct more research in Australia is a…

Lundbeck Limited (UK) If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview of how you have seen the company performing since you arrived in 2009, and what your outlook is for 2011?…